Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,591.3	$ 2,913.7
Marketable securities	1,269.1	1,562.2
Accounts receivable, net	2,092.6	1,880.5
Due from anti-CD20 therapeutic programs	511.6	590.2
Inventory	858.8	804.2
Other current assets	683.8	631.0
Total current assets	8,007.2	8,381.8
Marketable securities	969.5	1,408.1
Property, plant and equipment, net	3,281.6	3,247.3
Operating lease assets	422.0	427.0
Intangible assets, net	3,446.9	3,527.4
Goodwill	5,752.0	5,757.8
Deferred tax asset	3,109.4	3,232.1
Investments and other assets	1,130.6	1,252.8
Total assets	26,119.2	27,234.3
Current liabilities:
Current portion of notes payable	1,501.8	1,495.8
Taxes payable	310.0	71.4
Accounts payable	389.0	530.8
Accrued expenses and other	2,437.8	2,765.8
Total current liabilities	4,638.6	4,863.8
Notes payable	4,459.9	4,459.0
Deferred tax liability	2,722.8	2,810.8
Long-term operating lease liabilities	403.7	412.7
Other long-term liabilities	1,357.3	1,348.9
Total liabilities	13,582.3	13,895.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.1	0.0
Accumulated other comprehensive loss	(149.3)	(135.2)
Retained earnings	15,673.1	16,455.4
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	12,546.9	13,343.2
Noncontrolling interests	(10.0)	(4.1)
Total equity	12,536.9	13,339.1
Total liabilities and equity	$ 26,119.2	$ 27,234.3